Alphatec (ATEC) Q2 2026: Revenue Growth, Smaller Loss, and Heavy Capital Needs
Alphatec grew second-quarter revenue 15% and narrowed its loss, while instrument investment, debt costs, and cash use remain central.
signal:ATEC:2026-09-11 Alphatec (ATEC) Q2 2026: Revenue Growth, Smaller Loss, and Heavy Capital Needs
Alphatec’s second-quarter filing shows continued growth in its spine-surgery business and a narrower loss. It also shows a capital-intensive model: the company continues to invest heavily in surgical instruments and carries meaningful interest expense.
Revenue and loss
Revenue from products and services increased 15% to $213.5 million for the three months ended June 30, 2026, from $185.5 million a year earlier. Management attributed the increase to greater product volume, expansion of the surgeon user base, new products, and broader technology adoption.
Cost of sales rose only 5% to $59.4 million, but operating expenses increased 10% to $156.0 million. Sales, general and administrative expense alone rose 13% to $134.0 million as compensation, variable selling costs, and distribution investment increased.
The quarterly net loss narrowed to $25.8 million, or $0.16 per share, from $41.1 million, or $0.27 per share. The result included $11.9 million of debt-extinguishment loss and $11.0 million of net interest expense.
Cash and capital intensity
Operating cash flow for the first six months was positive $21.8 million, up from $10.5 million. Alphatec nevertheless spent $32.0 million on property and equipment and $4.4 million on intangible assets. Cash fell to $118.7 million from $160.8 million at year-end after investing and financing outflows.
Surgical instruments represented $326.5 million of gross property and equipment at June 30. That deployment supports adoption, but it makes growth dependent on disciplined utilization and capital allocation.
What matters next
- Revenue growth relative to selling and distribution expense.
- Progress toward sustained GAAP profitability, not only a smaller loss.
- Instrument utilization and capital expenditure requirements.
- Interest expense and refinancing risk as borrowing sources mature.
Unsupported volume, valuation, macro and preset trading claims in the original article were removed. This is a filing-based review, not investment advice.